Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights
James Yu,Robin Park,Richard Kim
DOI: https://doi.org/10.2147/JHC.S341195
2023-07-19
Journal of Hepatocellular Carcinoma
Abstract:James Yu, 1 Robin Park, 1 Richard Kim 2 1 Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2 Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Correspondence: Richard Kim, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, CSB 8TH 8173, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA, Tel +1 813 745 1813, Fax +1 813 449 6749, Email The systemic therapy landscape for hepatocellular carcinoma is rapidly evolving, as the recent approvals of checkpoint inhibitor-based regimens such as atezolizumab–bevacizumab and durvalumab–tremelimumab in advanced disease have led to an expanding therapeutic armamentarium. The development of biomarkers, however, has not kept up with the approvals of new agents. Nevertheless, biomarker research for hepatocellular carcinoma has recently been growing at a rapid pace. The most active areas of research are biomarkers for early detection and screening, accurate prognostication, and detection of minimal residual disease following curative intent therapies, and, perhaps most importantly, predictive markers to guide selection and sequencing of the individual agents, including tyrosine kinase inhibitors and immunotherapy. In this review, we briefly summarize the recent developments in systemic therapeutics for hepatocellular carcinoma, introduce the key completed and ongoing prospective and retrospective studies evaluating diagnostic, prognostic, and predictive biomarkers with high clinical relevance, highlight several potentially important areas of future research, and share our insights for each biomarker. Keywords: hepatocellular carcinoma, diagnostic biomarker, prognostic biomarker, predictive biomarker, novel biomarker Hepatocellular carcinoma (HCC) is the most common liver primary cancer and the second leading cause of cancer-associated death worldwide. 1 Although there are established HCC surveillance systems, more than 50% of HCC patients present with advanced disease, which limits them from receiving curative treatment such as surgical resection or liver transplantation (LT). 2,3 Alpha-fetoprotein (AFP) is the most widely used biomarker for HCC surveillance, in conjunction with ultrasound (US). 4,5 However, the exact role of AFP in surveillance is somewhat controversial. No other biomarkers have been incorporated into daily practice for HCC surveillance in the major guidelines. 4,5 There is an unmet need for the development of biomarkers for the early detection of HCC. Since 2008, there have been remarkable improvements in novel systemic therapy for HCC. During this period, more than a dozen therapies, predominantly tyrosine kinase inhibitors (TKIs), anti-angiogenesis agents, and immune checkpoint inhibitors (CPIs), have been approved as first or later-line therapies, and have significantly extended survival in advanced HCC. However, only around 27% of HCC patients respond to the atezolizumab–bevacizumab combination, which is one of the standard first-line therapies for HCC at the time of publication. 6 Also, emerging data have indicated that the clinical benefit of HCC from CPIs and TKIs may be dependent on the etiology of HCC. 7–9 These heterogeneous responses to each treatment imply that finding novel predictive biomarkers could potentially elucidate which subgroup of HCC can achieve maximal clinical benefit from specific novel therapies. Along with this dynamic development of new agents in HCC, a huge number of studies have been performed that propose potential predictive biomarkers for each novel agent. However, except for AFP for ramucirumab, most of those proposed biomarkers have not been used in clinical practice. 10 Therefore, there is an unmet necessity to develop and verify better predictive biomarkers for each novel therapy. In recent years, there have been an emerging developments in omics technology, such as cell-free DNA (cfDNA), including circulating tumor DNA (ctDNA), micro-RNA (miRNA), and circulating tumor cells (CTCs), which can potentially lead to novel diagnostic, prognostic, and predictive biomarkers in HCC. In this review, we discuss the current evidence on early diagnostic, prognostic, and predictive HCC biomarkers, share our insights, and present a comparative discussion for each novel biomarker. The Early Detection Research Network (EDRN) proposed five phases of biomarker development for early cancer detection that have been widely used in the field. 11 In 2021, the International Liver Cancer Association (ILCA) suggested modified EDRN biomarker phases tailored to HCC. 12 Phase 1 is an exploratory study to find potential biomarkers in preclin -Abstract Truncated-
oncology